OR-FLIR-SYSTEMS-INC
22.1.2019 17:01:13 CET | Business Wire | Press release
FLIR Systems, Inc. (NASDAQ: FLIR) today announced the Raymarine DockSense™ assisted docking system, the marine industry’s first intelligent object recognition and motion sensing assisted docking solution for recreational boating. DockSense system uses FLIR machine vision camera technology and video analytics to integrate intelligence gathered from surrounding imagery with the vessel’s propulsion and steering system to assist boat owners in tight quarter docking maneuvering. Additionally, FLIR announced that Prestige Yachts, a Groupe Beneteau brand, will become the first to demonstrate the technology.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190122005313/en/
Docking a boat can be a stressful experience, even for the most experienced captains. Often wind and tides make the task more difficult, and docking mishaps can become expensive repairs and safety hazards. The DockSense system is designed to augment a captain's boat handling skills using the system’s Virtual Bumper™ zone technology around the vessel. Should an object like a piling or another vessel encounter the Virtual Bumper, DockSense automatically introduces corrective steering and throttle commands to avoid the object and assist the captain in guiding the vessel to the dock.
DockSense uses global positioning system (GPS) and attitude heading reference system (AHRS) position sensing technology to compensate for the effects of wind and currents, ensuring the vessel enters the dock without drama or costly collisions. The Raymarine DockSense system includes multiple FLIR machine vision cameras, a central processing module, and the DockSense App running on Raymarine’s Axiom navigation display. The system integrates with modern joystick propulsion systems, providing assisted steering and throttle commands to help captains make a smooth arrival.
“Raymarine DockSense assisted docking system embodies our focus on solutions by combining FLIR navigation, machine learning, and sensing technologies,” said Jim Cannon, President, and CEO of FLIR. “Most importantly, we bring these innovations together into a simple solution that addresses a key customer challenge by taking the stress out of docking a boat and makes the boating experience safer and more enjoyable for everyone onboard.”
“Our goal is to be the global benchmark for all boating experiences,” said Hervé Gastinel, CEO of Groupe Beneteau. “The Raymarine DockSense solution will give future Prestige owners the confidence to dock safely and aligns with our vision to simplify the boating experience and make boating accessible to a much larger audience”, confirms Erik Stromberg, Prestige product marketing director.
FLIR will preview Raymarine DockSense technology at the Dusseldorf Boat Show in, Germany from January 19 – 27 at the Raymarine stand (Hall 11, Stand A42 ) and the Prestige stand (Hall 6, Stand D57). DockSense will also be demonstrated on a Prestige 460 motor yacht during the Miami Boat Show in February 2019.
To learn more, visit http://www.raymarine.com/docksense .
About FLIR Systems
Founded in 1978 and headquartered in Wilsonville, Oregon, FLIR Systems is a world-leading maker of sensor systems that enhance perception and heighten awareness, helping to save lives, improve productivity, and protect the environment. Through its nearly 3,500 employees, FLIR's vision is to be "The World's Sixth Sense" by leveraging thermal imaging and adjacent technologies to provide innovative, intelligent solutions for security and surveillance, environmental and condition monitoring, outdoor recreation, machine vision, navigation, and advanced threat detection. For more information, please visit http://www.flir.com and follow @flir .
About Prestige
A major international brand, PRESTIGE has positioned itself in the highly exacting market of luxury motor yachts. Manufactured in Vendée – France and devised by yachtsmen for those who love the sea, PRESTIGE® yachts are the jewel of French marine engineering. With the Garroni Studio, PRESTIGE designs the most livable yachts from 40 to 75 feet. Both FLYBRIDGE and SPORT ranges offer contemporary, high-design and clever motor yachts. The brand relies on an ever-growing worldwide professional dealer network. For more information please visit http://www.prestige-yachts.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190122005313/en/
Contact:
FLIR Media Contact Tim McDowd 503-498-3146 tim.mcdowd@flir.com
FLIR Investor Relations Jay Gentzkow 503-498-3809 Jay.gentzkow@flir.com
Prestige Press contact Elise Vinet +33670643397 e.vinet@jeanneau.fr
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom